Skip to content

Comparison of treatment for chronic subdural hematoma

Comparison of treatment for chronic subdural hematoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100050332
Enrollment
Unknown
Registered
2021-08-26
Start date
2021-09-01
Completion date
Unknown
Last updated
2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic subdural hematoma

Interventions

Endoscope group:Endoscope therapy
Interventional group:Interventional therapy
Medicine group:Medicine therapy
Medicine and interventional group:Medicine and interventional therapy
Drilling and drainage group:Drilling and drainage

Sponsors

Beijing Tiantan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Good medical condition; 2.Patients with chronic subdural hematoma over 18 years old.

Exclusion criteria

Exclusion criteria: 1.CSDH with focal location (confined to the frontal lobe or temporal base or interhemispheric space, without cerebral convex involvement), thickness less than or equal to 10 mm, or no mass effect (cortical flattening or midline displacement); 2.CSDH that developed with underlying conditions (vascular lesions, brain tumor, arachnoid cyst, spontaneous intracranial hypotension, or previous craniotomy); 3.Life expectancy of less than 6 months.

Design outcomes

Primary

MeasureTime frame
Hematoma recurrence;Hematoma progression;Reduced hematoma;

Countries

China

Contacts

Public ContactLiu Aihua, Hu Zhiqiang

Beijing Tiantan Hospital, Capital Medical University

15901398688@163.com+86 15901398688

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026